Stockscreener 앱 받기
48.91
0.13%
0.065
Ptc Therapeutics Inc 주식(PTCT)의 최신 뉴스
PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst (NASDAQ:PTCT) - Seeking Alpha
Morgan Stanley lowers PT for PTC Therapeutics to $71 from $76. - AInvest
RBC says PTC Therapeutics CRL may signal difficulty for Biohaven - Yahoo Finance
PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital - Yahoo Finance
Charles Schwab Investment Management Inc. Cuts Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics' (NASDAQ:PTCT) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
FDA slaps CRL on PTC Therapeutics’ vatiquinone NDA - The Pharma Letter
PTC stung by FDA decision not to approve rare disease drug - pharmaphorum
PTC’s vatiquinone approval hopes dashed in Friedreich’s Ataxia - Yahoo Finance
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided - MSN
PTC Therapeutics, Inc. $PTCT Shares Sold by US Bancorp DE - MarketBeat
PTC Therapeutics, Inc. $PTCT Position Increased by Sector Gamma AS - MarketBeat
Nuveen LLC Acquires Shares of 1,009,168 PTC Therapeutics, Inc. $PTCT - MarketBeat
US FDA declines to approve PTC Therapeutics’ rare genetic disorder drug - WKZO
Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection - insights.citeline.com
PTC Therapeutics stock falls as FDA issues CRL for vatiquinone in FA - Investing.com Canada
PTC Therapeutics Shares Drop After FDA Rejects Vatiquinone Application - MSN
PTC Therapeutics stock price target lowered to $63 at Jefferies on FDA rejection - Investing.com
PTC Therapeutics Surges on Q2 Earnings and Strategic Moves - StocksToTrade
US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder - Reuters
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns - inkl
100,000 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Public Sector Pension Investment Board - MarketBeat
US FDA declines to approve PTC Therapeutics' rare genetic disorder drug - Reuters
FDA rejects PTC’s Friedreich’s ataxia drug - Endpoints News
PTC Therapeutics Receives FDA Complete Response Letter - MSN
PTC Therapeutics rare disease therapy rejected (PTCT:NASDAQ) - Seeking Alpha
PTC Therapeutics stock falls after FDA rejects vatiquinone application - Investing.com
PTC Therapeutics Says FDA Issues CRL For Vatiquinone NDA In Friedreich's Ataxia - Nasdaq
Ptc Therapeutics receives complete response letter for Vatiquinone NDA - MarketScreener
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA | PTCT Stock News - GuruFocus
PTC Therapeutics and the FDA's August 19, 2025 PDUFA Deadline for Vatiquinone: Navigating Risk and Reward in Orphan Drug Development - AInvest
FDA Denies Approval: PTC Therapeutics' Vatiquinone for Rare Genetic Disease Friedreich's Ataxia Hits Setback - Stock Titan
PTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds - Yahoo Finance
Is PTC Therapeutics Inc. stock a good dividend stockJuly 2025 Momentum & High Win Rate Trade Alerts - theviewers.co.kr
PTC Therapeutics, Inc. $PTCT Holdings Raised by Deutsche Bank AG - MarketBeat
PTC Therapeutics Gains FDA Approval for Sephience - MSN
Vanguard Group Inc. Has $438.63 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2025 Earnings Call Transcript - MSN
Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Price Target at $69.85 - MarketBeat
Leerink Partnrs Predicts Lower Earnings for PTC Therapeutics - MarketBeat
PTC Therapeutics upgraded at BofA on FDA review for Friedreich's ataxia drug - MSN
PTC Therapeutics’ SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com South Africa
Behind the Scenes of PTC Therapeutics's Latest Options Trends - Benzinga
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Lowered by Wall Street Zen - MarketBeat
PTC Therapeutics’ SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Ptc Therapeutics, Inc. shares rise 6.59% intraday after presenting at Oppenheimer 28th Annual Tech Conference. - AInvest
PTC Therapeutics: Stock Rises Amid Mixed Signals - TipRanks
Phenylketonuria Market to Witness Promising Upswing by 2034, - openPR.com
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com
RBC Capital Initiates PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $63 - 富途牛牛
PTC Therapeutics’ Earnings Call Highlights Sephience Success - MSN
0.95%
0.57%
자본화:
|
볼륨(24시간):